What happened
The life sciences industry is highly globalized, although EY estimates that the US accounted for 45% of new pharmaceutical products2 and 51% of all global drug sales3 in 2024. China is a primary source of raw materials and manufacturing and a growing source of innovation, while Europe is a key manufacturer of complex biological products, and India the world’s largest producer of generic drugs.
Recent US policy announcements – including the announcement of tariffs on medical devices and plans to tariff pharmaceutical imports, the push for Most Favored Nation (MFN) pricing agreements with pharmaceutical companies and the reduction of National Institutes of Health funding of biomedical research – are accelerating a potential geographical re-balancing of the industry.
What’s next
US policies may boost investment in some life sciences manufacturing and R&D sites in the US, and could prompt some companies to reassess operations in Europe previously influenced by tax and regulatory advantages among other strategic considerations.
President Trump has said the US will eventually impose new tariffs on finished pharmaceutical products, following a national security review. Even without these, tariffs on raw materials are expected to drive up logistical costs and ultimately increase prices. Tariffs on pharmaceuticals could also lead to shortages and stockouts.
Prices in other markets could increase in tandem with US prices, but European single-payer systems are unlikely to accommodate these increases, so potential “drug loss” and “drug lag” there are possible (such as is already seen in Japan, albeit for different reasons).
Business impact
Uncertainty around the industry’s future revenue model has contributed to reduced venture capital (VC) and M&A investment in the US and European life sciences start-up sectors, the major traditional source of life sciences innovation. The industry may increase its investment on Chinese R&D, which continues to flourish.
Policy changes may drive fundamental re-orientation among life sciences companies. Pharmaceutical supply chains, for example, may shift from globalized to a mix of global and regional sites with some onshoring and some outsourcing to balance cost, regulatory compliance and flexibility.